Loading…
Research
Ayurveda has no shortage of claims. Where one of our formulations has been studied, we publish what was measured, with the authors' own caveat. Where it hasn't, we say so.
Published research · IMMBO and allergic rhinitis
In 2023 an open-label randomised controlled trial of IMMBO in allergic rhinitis was published in Cureus and indexed on PubMed Central. It compared IMMBO against a conventional combination of levocetirizine and montelukast over 28 days.
Design 250 patients enrolled, 224 randomised 1:1. IMMBO group n=114 at 60 mg/kg/day in three divided doses; comparison group n=110 on levocetirizine 2.5 mg plus montelukast 4 mg once daily. Assessed at baseline, day 14 and day 28.
No serious adverse events were reported in either group. The authors describe the trial as establishing prima facie evidence, and note it requires further scientific development to confirm long-term benefit.
Published as
Prakash VB, Rao YK, Prakash S, Sati ST, Mohapatra A, Negi N. Proof of Efficacy Study to Evaluate an Ayurvedic Formulation in the Treatment of Allergic Rhinitis: An Open Label Randomized Controlled Clinical Trial. Cureus. 2023;15(10):e46663.
DOI 10.7759/cureus.46663 · PMID 37942368
Read the full paperWhere it comes from
Vaidya Balendu Prakash set up the Vaidya Chandra Prakash Cancer Research Foundation in his father's memory, to bring scientific study to Ayurveda. Most of the work on IMMBO comes from it. The published trial above has authors from GSVM Medical College, Kanpur, as well.
Four further laboratory and animal studies of IMMBO come from the Foundation. They are not yet published in a journal we can cite, so we don't summarise them here.
What has not been studied
Our other medicines are classical preparations, made by the principles of Rasa Shastra. We don't claim results for them that no study has measured. Take them on the advice of a qualified Ayurvedic physician.